Effect of Thymoquinone Extracted From Nigella Sativa in the Treatment of Arsenical Keratosis

Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (Other)
Overall Status
Recruiting
CT.gov ID
NCT04686461
Collaborator
(none)
34
1
1
16.1
2.1

Study Details

Study Description

Brief Summary

Prepare an ointment from Nigella sativa seeds extract and apply it over palmer arsenical keratosis patient for 12 weeks. After than the effect of the ointment will be observed by measuring the keratotic nodular size before and after the intervention.

Condition or Disease Intervention/Treatment Phase
  • Drug: Nigella sativa seeds extract containing ointment intervention
N/A

Detailed Description

Arsenicosis is a massive public health problem affecting thousands of people worldwide, especially India, West Bengal, and Bangladesh. In our country groundwater of estimated 59 administrative districts have been contaminated with high concentration of arsenic. Through this contaminated drinking water a large number of populations are chronically exposed to high concentration of arsenic. Arsenicosis is characterized by diffuse melanosis followed by hyperpigmentation and keratosis. Keratosis causes reduce working capacity that affects socioeconomic condition of the patient. Invasive skin lesions like squamous cell carcinoma, Bowen's disease, and basal cell carcinoma also caused by it. Keratosis can treated by several topical preparation like propylene glycol, salicylic acid, alpha-lipoic acid, neem leaf extract, solanum melongena extract, Azadirachta indica and oral preparation like zinc, antioxidant, and folic acid. This treatment procedure required longer time to relieve symptom and reduce patient's compliance. Nigella sativa is a well-known spice of Southeast Asia, especially in Bangladesh. It contains a yellow volatile oil, a fixed oil, protein, amino acid, reducing sugars, alkaloids, and minerals like potassium, sodium, phosphorus, and iron while zinc, magnesium, calcium, copper, and manganese are found in low level. Thymoquinone is a main pharmacologically active constituent of volatile oil of N. sativa. Other constituents of the volatile oil are thymol, thymohydroquinone, and dithymoquinone. These biologically active compounds possess antimicrobial, anti-inflammatory, antioxidant, immunological, antimetastatic, anti-diabetic activity. Study with Nigella sativa in the treatment of arsenical keratosis was done and found effective. Therefore, the study will be done to identification of compound that is isolated from Nigella sativa and its effect on moderate to severe arsenical keratosis. . After obtaining clearance from IRB, on the basis of selection criteria, 34 patients of arsenical keratosis will be enlisted from Bhanga Upazilla of Faridpur district, an arsenic affected area. The study will be an experimental study and conducted in Bangabandhu Sheikh Mujib Medical University. Nigella sativa extract will be collected by using n-hexane as a solvent and rotary evaporator. Thin Layer Chromatography (TLC), Nuclear Magnetic Resonance (NMR) and Infrared (IR) spectrometry of the extract will be done to identify compound. Cytotoxicity test of the extract will be analyzed by using brine shrimp bioassay. . Then a topical ointment will be prepared from Nigella sativa extract and supplied to the arsenical keratosis patient at two weeks interval. Instruction about the application of the ointment on keratotic lesion will be given to the patients. Adherence and side effects of the ointment will be monitored at regular interval over phone calls and during field visit. Keratotic nodular size will be measured before start and after completion of treatment. Photograph will also take before and after treatment. Improvement of the lesion will be measured by mean scoring of nodule and perception of patients about their improvement by using Likert Scale. Statistical analysis and results will be presented in tabulated forms and in different diagrams.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
34 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of Thymoquinone Extracted From Nigella Sativa in the Treatment of Arsenical Keratosis
Actual Study Start Date :
Oct 20, 2019
Anticipated Primary Completion Date :
Jan 20, 2021
Anticipated Study Completion Date :
Feb 20, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Nigella sativa seeds extract containing ointment intervention

Nigella sativa seeds extract containing ointment dose- twice daily for 12 weeks

Drug: Nigella sativa seeds extract containing ointment intervention
Nigella sativa seeds extract containing ointment Nigella sativa seed extract, bee wax, white petrolatum, stearyl alcohol

Outcome Measures

Primary Outcome Measures

  1. Keratotic nodular size [12 weeks]

    Lesion size will be measured by slide calipers

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age: 19 - 65 years

  • Arsenical keratosis: Presence of moderate to severe keratosis (>5 mm) in both palms or soles

  • Drinking arsenic-contaminated water (>50 µg/ L) for at least more than six months

  • Patient did not receive topical application of any drug for the last three months

  • Patient agreed to participate voluntarily

  • Patient who understood the instruction of applying drug and could apply drug as per an instruction

Exclusion Criteria:
  • Age <19 and >65 years

  • Pregnant and nursing mother

  • Patient who received any treatment of arsenicosis within the last three months

  • Patient with skin diseases like atopic dermatitis, eczema, and psoriasis

  • Any systemic disease, inflammatory disease and infectious condition that affected the skin, for example, diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus and hepatitis

  • Food allergy to Nigella sativa

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bhanga Faridpur Bangladesh

Sponsors and Collaborators

  • Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Investigators

  • Principal Investigator: Bangladesh Bhanga, Faridpur, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Farhana Nargis, MD, Resident, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
ClinicalTrials.gov Identifier:
NCT04686461
Other Study ID Numbers:
  • BSMMU/2020/1642
First Posted:
Dec 28, 2020
Last Update Posted:
Jan 8, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 8, 2021